Results 21 to 30 of about 1,866 (169)

Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies

American Journal of Clinical Dermatology
Nail psoriasis can have a substantial negative impact on both the physical and emotional well-being of patients, and is a risk factor for psoriatic arthritis.
J. Merola, Richard B. Warren, D. Thaçi, Kenneth B. Gordon, Emi Nishida, B. Strober, Curdin Conrad, Sarah Kavanagh, J. López-Pinto, B. Hoepken, P. Gisondi   +10 more
semanticscholar   +2 more sources

Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies [PDF]

RMD Open
Objective To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) in the phase ...
Annelies Boonen, Atul Deodhar, Martin Rudwaleit, Lianne S Gensler, Karl Gaffney, Maureen Dubreuil, Victoria Navarro-Compán, Vanessa Taieb, Carmen Fleurinck, Ute Massow, Thomas Vaux, Michael F Mørup, Christine de la Loge   +12 more
doaj   +2 more sources

Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies [PDF]

ACR Open Rheumatology
Objective The objective of this study was to assess 52‐week efficacy and safety of bimekizumab in patients with active psoriatic arthritis (PsA) with or without concomitant methotrexate (+/−MTX) treatment at baseline.
Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Alice B. Gottlieb   +10 more
doaj   +2 more sources

Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis [PDF]

Rheumatology and Therapy
Introduction A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to IL-17A, versus other treatments for patients with radiographic axial spondyloarthritis (r-axSpA; i.e.
Walter P. Maksymowych, Howard Thom, Michael F. Mørup, Vanessa Taieb, Damon Willems, Nikos Lyris, Karl Gaffney   +6 more
doaj   +2 more sources

Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT

Dermatology and Therapy
Introduction While bimekizumab has demonstrated rapid, superior clinical efficacy versus adalimumab and ustekinumab, with sustained responses through 4 years, its comparative and long-term impact on patient-reported outcomes (PROs) remains underexplored.
April Armstrong, Kim A. Papp, Mark Lebwohl, Laura J. Savage, Keiichi Yamanaka, Diana Elena Vlase, Rhys Warham, Jérémy Lambert, José M. López Pinto, Krista Wixted, Diamant Thaçi   +10 more
doaj   +2 more sources

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Dermatology Practical & Conceptual
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment.
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, Antonio Costanzo   +44 more
doaj   +2 more sources

Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies

ACR Open Rheumatology
Objective To assess two‐year impact of bimekizumab on patient‐reported outcomes (PROs), and their association with objective measures of inflammation, in patients with psoriatic arthritis (PsA) who were biologic disease‐modifying antirheumatic drug ...
Laure Gossec, William Tillett, Laura C. Coates, Philip J. Mease, Maarten deWit, Dafna D. Gladman, Ana‐Maria Orbai, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jérémy Lambert, Patrick Healy, M. Elaine Husni   +12 more
doaj   +2 more sources

Predictive factors for early super response to bimekizumab in 341 patients with psoriasis—a 24-week short-term multicenter real-life experience

Journal of Dermatological Treatment
Purpose/Aim of the study: The efficacy of bimekizumab was shown in moderate to severe plaque psoriasis. The aim of this study was to investigate the early super responder (ESR) profile (at week 4) to bimekizumab.Materials and Methods: We performed a ...
Tubanur Çetinarslan, Muhammed Ali Mergen, Aylin Türel Ermertcan, Emel Bülbül Başkan, Serkan Yazıcı, İsa An, Gülhan Gürel, Esra Adışen, Abdullah Demirbaş, Recep Dursun, Bahadır Aslancan, Zeynep Topkarcı, Mustafa Esen, Zafer Türkoğlu, Dilek Canat, Selim Kandiş, Arzu Kılıç, İlgen Ertam Sağduyu, Elif Irmak Yazıcı, Ece Gökyayla, Neslihan Demirel Öğüt, Özge Sevil Karstarlı Bakay, Selami Aykut Temiz, Vefa Aslı Erdemir, Fatma Aslı Hapa, Ömer Aydin, Pelin Hızlı, Berna Solak, Melike Bütüner, Sema Aytekin, Hülya Albayrak, Munise Daye, Ümit Türsen, Ayşe Nur Sarıbaş Yıldırım, Beyhan Cengiz Özyurt   +34 more
doaj   +2 more sources

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

Dermatology and Therapy
Introduction Patient demographics, disease characteristics, and treatment history can impact the efficacy of biologic treatments in patients with psoriasis. Understanding the efficacy of biologics, such as bimekizumab, across diverse patient subgroups is
Bruce Strober, Wolf-Henning Boehncke, James G. Krueger, Nina Magnolo, Ronald Vender, Richard B. Warren, José Manuel López Pinto, Sarah Kavanagh, Bengt Hoepken, Paolo Gisondi   +9 more
doaj   +2 more sources

Real World Evidence of Secukinumab and Bimekizumab in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

Actas Dermo-Sifiliográficas
Background and objectives: Evidence for secukinumab and bimekizumab in hidradenitis suppurativa (HS) primarily comes from randomized clinical trials with selected patient populations.
S. Haselgruber, D. Muñoz-Barba, A. Soto-Moreno, C. Cuenca-Barrales, S. Arias-Santiago, A. Molina-Leyva   +5 more
doaj   +2 more sources